Valuation : CASI Pharmaceuticals, Inc.

Market Cap 2.88M 2.48M 2.35M 2.13M 3.99M 275M 4.01M 27.88M 10.72M 140M 10.81M 10.57M 442M P/E 2024
-1.11x
P/E 2025 -0.33x
Enterprise Value 24.73M 21.31M 20.18M 18.29M 34.31M 2.36B 34.48M 240M 92.15M 1.2B 92.88M 90.84M 3.8B EV / Sales 2024
1.75x
EV / Sales 2025 1.9x
Free-Float
53.62%
Yield 2024 *
-
Yield 2025 -
1 week 0.13
Extreme 0.1288
0.14
1 month 0.13
Extreme 0.1288
0.16
3 years 0.05
Extreme 0.05
8.48
5 years 0.05
Extreme 0.05
15.7
10 years 0.05
Extreme 0.05
88.92
Manager TitleAgeSince
Chief Executive Officer 62 21/07/2025
Director of Finance/CFO 44 16/05/2025
Chief Operating Officer 54 01/01/2017
Director TitleAgeSince
Director/Board Member 62 21/07/2025
Chairman 60 17/11/2025
Director/Board Member 62 01/04/2013
Change 5-day change 1-year change 3-year change Capi.($)
+8.69%-8.50% - - 2.88M
-0.65%-2.93%+47.70%+86.17% 994B
-0.29%-3.51%+49.15%+62.35% 640B
+0.83%+0.26%+17.76%+72.25% 454B
-0.38%-3.59%+30.13%+35.17% 337B
-0.09%-13.54%+13.34%+24.95% 261B
-0.43%-2.48%-0.73%+9.58% 246B
-1.34%-13.70%+36.53%+44.96% 204B
-3.44%-7.51%-20.63%-59.44% 190B
-0.75%-4.82%+25.46%+87.14% 178B
Average -0.73%-5.76%+22.08%+40.35% 389.42B
Weighted average by Cap. -0.51%-4.42%+30.96%+54.95%

Financials

2024 2025
Net sales 28.54M 24.59M 23.28M 21.1M 39.59M 2.73B 39.79M 277M 106M 1.39B 107M 105M 4.38B 20.71M 17.85M 16.9M 15.32M 28.73M 1.98B 28.88M 201M 77.17M 1.01B 77.79M 76.08M 3.18B
Net income -39.26M -33.82M -32.03M -29.03M -54.46M -3.75B -54.74M -380M -146M -1.91B -147M -144M -6.03B -48.06M -41.41M -39.21M -35.54M -66.67M -4.59B -67.01M -466M -179M -2.34B -180M -177M -7.38B
Net Debt 6.05M 5.21M 4.94M 4.47M 8.39M 578M 8.44M 58.62M 22.54M 294M 22.72M 22.22M 929M 21.85M 18.83M 17.83M 16.16M 30.32M 2.09B 30.47M 212M 81.43M 1.06B 82.07M 80.27M 3.36B
Logo CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Company’s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Company’s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.
Employees
-
Date Price Change Volume
11/09/26 $0.000000 -100.00% 146
10/09/26 $0.1400 +8.69% 3,015
09/09/26 $0.1288 -4.59% 6,342
08/09/26 $0.1350 -11.76% 12,155
04/09/26 $0.1530 0.00% 682

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!